mercredi 24 août 2016

Onco Actu du 24 août 2016

1. Biologie

An ecological approach to understanding differential cancer susceptibility in organs [The Evolution and Medicine Review]

2.8 Etiologie - Contraceptifs, THS

Combined HRT breast cancer risk 'may have been underestimated' [NHS Choices]

3.3 Prévention - Vaccins

Parents remain leery of schools that require HPV vaccination [STAT]

5.12 Immunothérapies

Not So Fast on the PD-L1 Comparisons [In the Pipeline]

5.12.2 Immunothérapies - CAR-T

Experimental cancer therapy holds great promise — but at great cost [STAT]

5.2 Pharma

Wall Street looks for Clovis to make good in ovarian cancer, after lung cancer failure [FierceBiotech]

FDA Accepts Clovis Oncology's New Drug Application for Rucaparib for Priority Review for the Treatment of Advanced Mutant BRCA Ovarian Cancer [Clovis Oncology]

5.4 Traitements - Economie

Drug Manufacturers Use Patents To Protect High Prices [NPR]

NICE approves new cancer drugs for routine NHS use [NICE]

Can anything contain U.S. drug costs? [Reuters]

6.1 Observation

Cancer was slated to overtake heart disease as America’s top killer — here’s why it hasn’t [STAT]

6.6 Publications

Scientific Reports On Track To Become Largest Journal In The World [The Scholarly Kitchen]

6.7.3 DMP

Evolutionary Pressures on the Electronic Health Record:  Caring for Complexity [JAMA]